# Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

> **NCT03631862** · PHASE4 · UNKNOWN · sponsor: **Zhengzhou University** · enrollment: 100 (estimated)

## Conditions studied

- Newly Diagnosed Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** CHOP Regimen

## Key facts

- **NCT ID:** NCT03631862
- **Lead sponsor:** Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631862, "Treatment of Newly Diagnosed Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03631862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*